Breast Cancer Research and Treatment

, Volume 96, Issue 3, pp 245–250

Treatment-induced menstrual changes in very young (<35 years old) breast cancer patients

Authors

    • Department of Radiation oncology, Asan Medical Center, College of MedicineUniversity of Ulsan
  • Seung Do Ahn
    • Department of Radiation oncology, Asan Medical Center, College of MedicineUniversity of Ulsan
  • Seong Soo Shin
    • Department of Radiation oncology, Asan Medical Center, College of MedicineUniversity of Ulsan
  • Sang-wook Lee
    • Department of Radiation oncology, Asan Medical Center, College of MedicineUniversity of Ulsan
  • Eun Kyung Choi
    • Department of Radiation oncology, Asan Medical Center, College of MedicineUniversity of Ulsan
  • Jong Hoon Kim
    • Department of Radiation oncology, Asan Medical Center, College of MedicineUniversity of Ulsan
  • Byung Ho Son
    • Department of Surgery, Asan Medical Center, College of MedicineUniversity of Ulsan
  • Sei-Hyun Ahn
    • Department of Surgery, Asan Medical Center, College of MedicineUniversity of Ulsan
  • Woo Kun Kim
    • Department of Hematology Oncology, Asan Medical Center, College of MedicineUniversity of Ulsan
  • Sung Bae Kim
    • Department of Hematology Oncology, Asan Medical Center, College of MedicineUniversity of Ulsan
Clinical trial

DOI: 10.1007/s10549-005-9059-x

Cite this article as:
Kil, W.J., Ahn, S.D., Shin, S.S. et al. Breast Cancer Res Treat (2006) 96: 245. doi:10.1007/s10549-005-9059-x

Summary

Purpose

To evaluate the treatment-induced menstrual changes in very young (< 35 years old) breast cancer patients.

Methods and materials

We retrospectively examined the clinical records of 160 patients, ranging in age from 18 to 34 years old (median age, 32 years), treated between June 1992 and December 2002. One hundred twenty patients underwent mastectomy and 40 underwent breast conserving surgery. Postoperatively, 80 patients were treated with alkylating agent-based chemotherapy regimens (CMF) and 80 with anthracycline-based regimens (AD). In addition, 57 patients received adjuvant radiotherapy, and 77 received anti-estrogen therapy. Treatment-induced menstrual changes and present menstrual status were evaluated from hospital records and by one-to-one interviews. The median follow-up period was 54 months (range, 29–156 months).

Results

Treatment-induced menstrual change (amenorrhea) was occurred in 59 (36.9%) patients, 25 (31.3%) of those treated with CMF and 34 (42.5%) with AD (p=0.142). Amenorrhea occurred after a median 2 cycles of chemotherapy (range, 1–6 cycles). Menstruation resumed in 49 (83.1%) patients, 20 (80%) of those treated with CMF and 29 (85.3%) with AD (p=0.6). Median time to resumption of menstruation was median 3.5 months (range, 1–18 months) after amenorhrea. Disease recurred in 10 (16.9%) patients who experienced treatment-induced menstrual changes and in 18 (17.8%) of those who did not (p=0.89).

Conclusion

Although the overall incidence of treatment-induced menstrual change in breast cancer patients under age 35 was similar to that reported elsewhere, the rate of recovery from these change is higher. We observed no difference between CMF and AD treated patients in rates of amenorrhea or recovery from these changes.

Keywords

breast cancertreatment-induced menstrual changesvery young (<35 years old) age

Copyright information

© Springer 2006